Eindhoven, August 2025. Smart Biomaterials Consortium (SBMC) is pleased to welcome Heart Biotech Nano Ltd., a London-based innovator in regenerative cardiovascular technologies, as the newest member of its growing European network. The collaboration reflects a shared ambition to accelerate the development of advanced biomaterials that make a real difference for patients.
Heart Biotech Nano Ltd. focuses on bioengineered solutions for heart valve repair and cardiac tissue regeneration. One of its leading innovations is the Yacoub heart valve, a regenerative, cell-free valve designed to mimic natural biomechanics and encourage host cell colonization after implantation. The company combines material science with tissue engineering to create next-generation therapies for structural heart disease.
“Joining SBMC is a strategic step for us,” says Francis White, CEO of Heart Biotech Nano Ltd. “The consortium represents an ecosystem where science and application go hand in hand. We’re excited to be part of a community that shares knowledge, connects disciplines, and helps promising technologies move forward in the right direction. We’re committed to building next generation regenerative medical devices and contributing to breakthroughs in the scientific understanding of tissue engineering. By contributing our expertise and partnering within SBMC, we can help shape best practices at this frontier. We firmly believe in ‘category creation’ via collaboration: rather than going it alone, building a shared ecosystem lets the entire field move faster, smarter, and stronger.”
As part of the consortium, Heart Biotech Nano Ltd. gains access to SBMC’s innovation infrastructure in Eindhoven, including GMP-compliant cleanrooms on the High Tech Campus and a development laboratory on the campus of Eindhoven University of Technology (TU/e). Together, these facilities provide a unique setting for translating early-stage research into scalable, clinically relevant solutions.
“Heart Biotech brings valuable expertise in cardiovascular biomaterials to our community,” says Jan Rietsema, CEO of SBMC. “Their work on regenerative heart valves addresses a complex and high-impact clinical need. We are pleased to welcome them to the consortium and look forward to the scientific and strategic exchange that lies ahead.”
This new collaboration reinforces SBMC’s mission to serve as a European hub for regenerative biomaterials innovation, where cooperation, clinical relevance, and scientific excellence come together to benefit patients worldwide.
